Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.

IF 3.9 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Frontiers of Medicine Pub Date : 2023-10-01 Epub Date: 2023-07-04 DOI:10.1007/s11684-023-0993-y

Elias A T Koch, Anne Petzold, Anja Wessely, Edgar Dippel, Markus Eckstein, Anja Gesierich, Ralf Gutzmer, Jessica C Hassel, Harald Knorr, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Dirk Schadendorf, Max Schlaak, Kai-Martin Thoms, Selma Ugurel, Jochen Utikal, Michael Weichenthal, Beatrice Schuler-Thurner, Carola Berking, Markus V Heppt

{"title":"Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.","authors":"Elias A T Koch, Anne Petzold, Anja Wessely, Edgar Dippel, Markus Eckstein, Anja Gesierich, Ralf Gutzmer, Jessica C Hassel, Harald Knorr, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Dirk Schadendorf, Max Schlaak, Kai-Martin Thoms, Selma Ugurel, Jochen Utikal, Michael Weichenthal, Beatrice Schuler-Thurner, Carola Berking, Markus V Heppt","doi":"10.1007/s11684-023-0993-y","DOIUrl":null,"url":null,"abstract":"<p><p>Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A, n = 78) versus those without LDT (cohort B, n = 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months; P = 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months; P = 0.054). The objective response rate to any ICB (16.7% vs. 3.8%, P = 0.0073) and combined ICB (14.1% vs. 4.5%, P = 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"878-888"},"PeriodicalIF":3.9000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11684-023-0993-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A, n = 78) versus those without LDT (cohort B, n = 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months; P = 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months; P = 0.054). The objective response rate to any ICB (16.7% vs. 3.8%, P = 0.0073) and combined ICB (14.1% vs. 4.5%, P = 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.

查看原文本刊更多论文

肝脏导向治疗与转移性葡萄膜黑色素瘤生存率的提高和免疫检查点阻断反应的增加有关：一项回顾性多中心试验的结果。

葡萄膜黑色素瘤（UM）的转移灶主要扩散到肝脏。由于对全身治疗的反应率较低，肝脏导向疗法（LDT）通常用于控制肿瘤。肝脏导向疗法对全身治疗反应的影响尚不清楚。本分析共纳入了182名接受免疫检查点阻断疗法（ICB）治疗的转移性UM患者。患者来自前瞻性皮肤癌中心和德国皮肤病合作肿瘤学组（DeCOG）的德国国家皮肤癌登记处（ADOReg）。对两个队列进行了比较：LDT 患者（队列 A，n = 78）与非 LDT 患者（队列 B，n = 104）。数据分析包括治疗反应、无进展生存期（PFS）和总生存期（OS）。队列 A 的中位 OS 明显长于队列 B（20.1 个月 vs. 13.8 个月；P = 0.0016），队列 A 的 PFS 呈改善趋势（3.0 个月 vs. 2.5 个月；P = 0.054）。我们的数据表明，在转移性 UM 患者中，LDT 与 ICB 的联合治疗可能与生存获益和对 ICB 更高的治疗反应相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Medicine ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

18.30

自引率

0.00%

发文量

800

期刊介绍： Frontiers of Medicine is an international general medical journal sponsored by the Ministry of Education of China. The journal is jointly published by the Higher Education Press and Springer. Since the first issue of 2010, this journal has been indexed in PubMed/MEDLINE. Frontiers of Medicine is dedicated to publishing original research and review articles on the latest advances in clinical and basic medicine with a focus on epidemiology, traditional Chinese medicine, translational research, healthcare, public health and health policies.